Mass General, Harvard to Use Illumina Genotyping Tech in Large ALS Study | GenomeWeb
NEW YORK (GenomeWeb News) – Illumina today said researchers from Massachusetts General Hospital and Harvard Medical School will use data from its Sentrix HumanHap300 BeadChips and Infinium assay reagents to run a whole-genome association study of amyotrophic lateral sclerosis.
 
The 2,200-sample case/control study is the largest genetic study to date of ALS, according to study co-supervisor Adrian Ivinson, director of Harvard’s Center for Neurodegeneration and Repair.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.